NCT03529110: DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane

NCT03529110
Breast Cancer Type: HER2+
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 3
Drug Category: Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with spinal cord compression or active central nervous system (CNS) metastases, defined as untreated and symptomatic, or requiring therapy
https://ClinicalTrials.gov/show/NCT03529110

Comments are closed.

Up ↑